The Serum Response Factor (SRF) coactivator myocardin stimulates the transcription of multiple muscle genes during cardiac and smooth muscle development. Mouse embryos lacking myocardin die during the earliest stages of smooth muscle development and fail to express multiple smooth muscle marker genes in the embryonic dorsal aorta and other vascular structures. In this study, we used mutant embryonic stem cell lines to further define the role of myocardin in smooth muscle differentiation and vascular development. Misexpression of myocardin in undifferentiated muscle stem cells resulted in efficient activation of smooth muscle genes, and weaker activation of genes involved in cardiac and skeletal muscle differentiation. Remarkably, myocardin À/À embryonic stem cell lines differentiated into smooth muscle cells in vitro, although these cells expressed significantly decreased levels of smooth muscle contractile genes. Moreover, genetically labeled myocardin À/À ES cells were able to contribute to smooth muscle lineages in vivo. These results indicate that while myocardin function is sufficient for activation of SRFdependent muscle gene expression in multiple cell types, myocardin-independent mechanism(s) can suffice for expression in some smooth muscle lineages. D
Introduction
Smooth muscle cells (SMCs) play multiple physiological roles in the adult organism, providing critical functions in the cardiovascular, respiratory, genitourinary, and gastrointestinal systems. The embryonic origins of SMCs reflect this diversity. The SMCs of the cardiovascular system alone are derived from three distinct sources from two germ layers: ectodermallyderived neural crest cells contribute to the SMCs of the outflow tract and proximal aorta, and mesodermally-derived cells comprise the SMC layer of the coronary and other vessels (Hirschi and Majesky, 2004; Hungerford and Little, 1999) .
The molecular events that control this diversity of SMC origin and function largely consist of combinatorial interactions among several transcriptional regulators (Kumar and Owens, 2003) . In particular, Serum Response Factor (SRF), a member of the MADS (MCM1, Agamous, Deficiens, SRF) family of transcription factors, has been shown to be a critical regulator of SMC genes. SRF binds to a cis-regulatory element called a CArG box (of the consensus CC(A/T) 6 GG), which is found in the regulatory regions of many cardiac and skeletal muscle genes and almost all SM genes (Miano, 2003) . SRF activity is absolutely required in vivo for the development of SMCs (Miano et al., 2004) . The activity of SRF during SMC differentiation is regulated via interactions among several other proteins, including GATA-4 and GATA-6 (Oh et al., 2004; Yin and Herring, 2005) , Elk-1 , histone modifying enzymes (Cao et al., 2005) and the extraordinarily powerful transcriptional co-activator myocardin .
Myocardin was discovered as a coactivator of SRFdependent gene expression specifically expressed in cardiac and SMC lineages during development and was subsequently shown to be sufficient for the misexpression of CArG-dependent SMC genes in non-muscle cells in several gain-of-function assays (Chen et al., 2002b; Du et al., 2003; Wang et al., 2003; Yoshida et al., 2003) . Myocardin is such a strong activator of CArGdependent muscle genes that it can induce the expression of inappropriate CArG-dependent muscle genes in vitro, such as inducing skeletal and cardiac forms of a-actin when overexpressed in SMCs (Yoshida et al., 2004) , as well as in spinal cord neurons in vivo (Small et al., 2005) .
There are two other members of the myocardin family, the Myocardin Related Transcription Factors (MRTFs) -A and -B. Both of these proteins are widely expressed throughout development, and are likely to be functionally redundant with myocardin in some tissues. They both co-activate high levels of CArG-dependent gene transcription in vitro via an association with SRF . Depending on the conditions, MRTF-A is capable of activating 3-to 4-fold higher levels of expression of several CArG-dependent muscle genes than is myocardin (Du et al., 2004) . Recent work shows that a musclespecific signaling mechanism drives MRTF-A and -B into the nucleus, indicating that MRTF-A and -B almost certainly play some role in stimulating the expression of CArG-dependent muscle genes in muscle cells (Kuwahara et al., 2005) .
Consistent with its role in activation of SMC gene expression, knockout mice lacking myocardin die at E10.5, displaying severe defects in vascular development: the expression of CArG-dependent muscle genes is absent from the region where the dorsal aorta normally differentiates, and mutant yolk sacs appear avascular . This early lethality precludes detailed analysis of myocardin's role in SMC differentiation in other contexts, yet several observations suggest there must be myocardin-independent mechanisms that activate SMC genes in tissues other than the embryonic dorsal aorta. First, the CArG-dependent SMC marker genes SM22 and a SM actin are both expressed normally in tissues other than the dorsal aorta in E10.5 myocardin À/À embryos, such as the somites and the heart tube. Second, myocardin is only expressed in a subset of vascular and visceral SMC types during embryogenesis. The SMCs of the genitourinary system, for example, where myocardin is not expressed, must have an alternate mechanism to drive the expression of CArGdependent SMC genes such as SM-MHC and a SM actin . Recently, murine mesoangioblasts, developmentally important stem cells associated with the dorsal aorta, were shown to express multiple SMC genes in vitro in the absence of detectable expression of myocardin (Brunelli et al., 2004) . Finally, myofibroblasts do not appear to express myocardin yet can activate a subset of CArGdependent SMC genes including those encoding a SM actin and SM22 (Yoshida and Owens, 2005; Yoshida et al., 2003) .
In the present study, we used a variety of gain-and loss-offunction approaches to further investigate the sufficiency and necessity of myocardin for SMC differentiation. We show that myocardin functions to activate high levels of SMC genes in undifferentiated cells: misexpression of myocardin in proliferating skeletal myoblasts resulted in high levels of smooth muscle and some cardiac gene expression, while loss of myocardin function resulted in consistent decreases in SM gene expression in vitro. In vivo, ES cells null for myocardin were able to contribute to grossly normal visceral and vascular smooth muscle tissues. These findings reveal that, although myocardin is an extraordinarily potent activator of SMC gene expression, myocardin-independent pathways can drive SMC differentiation in vivo.
Materials and methods

Transcriptional profiling and cell culture
The human skeletal satellite cell line HSKM5 was derived as described (Cronin et al., 2004) . A derivative of these cells was cultured in growth medium until infection in serum-free medium with Ad-myocardin or Ad-h-galactosidase. Adenoviruses are described in . Infected cells were maintained in growth medium for 48 h, and total RNA was harvested using TRIzol (Invitrogen) following manufacturer's protocols. Total RNA was used as a template for reverse transcription using a T7 promoter-containing poly-dT primer. cDNA was labeled for oligonucleotide microarray transcriptional profiling using the Enzo BioArray labeling kit (Enzo Biochem, New York, NY). Labeled cRNA was then hybridized to the Affymetrix Human Genome HG-U133A and HG-U133B chips following the manufacturer's protocols (Affymetrix, Santa Clara, CA). Array analysis was performed using Microarray suite 5.0, using user-definable parameters at default settings; MAS reports of present vs. absent and increased/decreased vs. no change were used at default confidence intervals and measures of significance. These results were exported to Microsoft Excel and a Microsoft Access database developed at Academic Computing Services at the University of Texas Southwestern Medical Center for detailed classification and sorting of target genes by function according to Gene Ontology classification. Microarray results were verified for selected transcripts using TaqMan probes from ABI on an ABI 7000 SDS, normalizing to 18S rRNA using the delta -delta Ct method according to manufacturer's protocols (Applied Biosystems, Foster City, CA).
For prediction and curation of predicted CArG boxes in the promoter regions of candidate myocardin target genes, weak consensus CArG boxes deviating from the consensus CCHWDWWWGG by one or fewer nucleotides were located relative to the predicted start of transcription of one of the reference sequences listed in Entrez Gene in murine and human genomic sequence. Evolutionary conservation of some predicted CArG boxes was ascertained using rVISTA (http://rvista.dcode.org).
All of the transcriptional profiles developed in the course of these studies will be deposited in the Gene Expression Omnibus (GEO) database at NCBI and their accession numbers appended to this publication.
Generation of myocardin null ES cells, in vitro differentiation and analysis of in vitro differentiated cells
Uteri from myocardin À/+ mouse intercrosses were washed at E3.5 and the resulting blastocysts were plated on a layer of mitotically inactivated SNL feeder cells in standard ES cell medium including 20% FBS and LIF. Note that these cells were mixed 129 SvEvTac / C57BL/6. Resulting ES cell colonies were expanded on feeders in ES cell medium and genotyped. ES cell line genotype was confirmed using RT-PCR specific for the exon of myocardin deleted in the knockout allele on RNA from differentiated ES cell cultures. Male myocardin À/À and myocardin +/+ cell lines were differentiated in vitro according to three different protocols. Cells were differentiated as embryoid bodies formed in hanging drops of ES cell medium without LIF as described in (Metzger et al., 1995) . Cells were also differentiated simply by plating them at high density and removing LIF, following (Weitzer et al., 1995) . In order to obtain high levels of consistent SM differentiation, cells were also differentiated as embryoid bodies (EBs) in the presence of retinoids and cAMP as per (Sinha et al., 2004) . Cultures were examined microscopically on a daily basis to score the progress of differentiation. Differentiation cultures were grown until the indicated time point, then total RNA was harvested using TRIzol following the manufacturer's protocols. RNA from at least two cultures was pooled for each time point. 2 Ag of total RNA was used as a template for random-primed RT-PCR using SuperScript III (Invitrogen) according to manufacturer's protocols. Varying concentrations of this cDNA were used as template for PCR analysis, from 0.2 AL to 4 AL, depending on the expression level of the gene. Real time PCR analysis was performed using Taqman probes in an iCycler (BioRad). Real time PCR probes were of the following sequences: aSMA forward CGCTGTCAGGAACCCTGAGA, reverse CGAAGCC-GGCCTTACAGA, probe CAGCACAGCCCTGGTGTGCGAC; SM-MHC forward TGGACACCATGTCAGGGAAA, reverse ATGGACACAAGTGC-TAAGCAGTCT, probe AGAACACTAAACGACAGCAGAGCCCAGC; 18S forward CGGCTACCACATCCAAGGAA, reverse AGCTGGAAT-TACCGCGGC, probe TGCTGGCACCAGACTTGCCCTC. RT-PCR analysis using EtBr stained Agarose gels was performed on an iCycler using the following primer sequences: myocardin exon 8 forward primer: AGACCC-CAAACCAAAGGTGAAGAAGCTC, myocardin exon 10 reverse: GGAGC-TTGTGCTGCCAAAGGGGTAGAAG. Other RT-PCR primer sequences were from (Niu et al., 2005) Immunocytochemistry was performed as per (Sinha et al., 2004) .
Chimeric analysis
Mixed background myocardin À/+ mice were crossed to ROSA26/+ mice in a pure 129 background (Jackson Labs, Bar Harbor, ME) and male ES cell lines that were myocardin À/À , ROSA26/+ and myocardin À/+ , ROSA26/+ were obtained as described above. These lines were expanded and injected into the inner cell mass of wild type C57BL/6 blastocysts and implanted into pseudopregnant host dams. Dams were sacrificed at E12.5 of embryonic development and conceptuses removed, embryos were freed from amniotic membranes, the chest wall was punctured to expose the developing aorta to fixative and staining solution, and embryos were fixed for 1 h on ice in 4% paraformaldehyde in PBS. Embryos were then rinsed twice in PBS and stained overnight in X-gal staining solution (5 mM ferrocyanide, 5 mM ferricyanide, 2 mM MgCl2, 0.1% NP40, 1 mg/mL Xgal in dimethylformamide). Embryos were subsequently rinsed twice with PBS and post-fixed overnight at 4-C in neutral buffered formalin. Embryos were then rinsed twice with PBS and processed for paraffin-embedding. Paraffin sections were cut every 10 AM from anterior to the dorsal aorta to posterior to the thoracic extension of the lungs. E16.5 embryos were harvested, grossly dissected and fresh frozen in OCT embedding medium, then sectioned into 8 AM sections. These sections were dried, then fixed in cold acetone for 5 min and processed for immunohistochemistry or Xgal staining. Adult mice resulting from chimeric ES cell injections were sacrificed at P28 and the aorta, uterus, heart and liver were fixed in 4% paraformaldehyde at 4-C for 1 h, then stained for h-galactosidase activity overnight at 37-C.
Results
Myocardin misexpression in vitro results in the transcriptional stimulation of multiple types of muscle genes
Because some chromatin states are not permissive for transcriptional stimulation, we developed a transcriptional profile of the spectrum of genes activated by myocardin using skeletal myoblasts, a cell type predicted to have chromatin structure permissive for activation of muscle genes and to possess any muscle-specific co-factors required for muscle gene expression. Additionally, we reasoned that since myocardin is such a potent stimulator of transcription, the fact that skeletal muscle cells do not express endogenous myocardin (Chen et al., 2002b; Wang et al., 2001) would mean that the baseline levels of myocardin target genes in muscle would be lower than in smooth or cardiac muscle cells, hence providing a sensitized context in which to observe the effects of myocardin misexpression.
In comparison to cells in which h-galactosidase was misexpressed, myocardin altered the expression of more than four thousand transcripts (Fig. 1A ) but only 267 UniGene clusters were up-regulated more than 5-fold. This latter group likely includes most or all of the direct targets of myocardin. The known genes displaying the most dramatic up-regulation in response to myocardin all have predicted CArG boxes in their proximal promoter regions or in their first introns (Fig.  1C .) This list includes many of the genes previously shown to be bona fide targets of myocardin in vivo, with several notable exceptions. SM22, for example, was only stimulated 4.9-fold in response to Ad-myocardin, probably because the basal, myocardin-independent expression of SM22 is high (Table  1) , consistent with SM22 being expressed in developing skeletal muscle cells in a myocardin-independent fashion in vivo. Similarly, a cardiac and a SM actin, which are also expressed at appreciable levels in developing skeletal muscle cells in vivo, were both stimulated in response to myocardin misexpression, but were expressed at high levels at baseline in these cells and showed lower fold-changes than might be predicted (Table 1) . Changes in expression of selected cardiac, smooth and skeletal muscle marker genes were verified by real time PCR (Table 1) . Examination of the 21 known genes which were down-regulated greater than 10-fold in myoblasts in response to myocardin showed no muscle-specific genes, nor any genes previously described as being CArG-dependent (see complete microarray dataset in GEO), consistent with myocardin functioning primarily as a transcriptional activator.
A hand-curated list of muscle genes sorted by muscle type where possible shows that myocardin misexpression resulted in an almost uniformly strong activation of SMC genes, but only a moderate stimulation of cardiac and skeletal genes. 86% of a list of canonical SMC genes was stimulated by myocardin, while only 44% of cardiac genes and 37% of skeletal genes were. There were also significant differences in the degree to which myocardin activated each of these categories of genes. Averaging the fold-change among all the transcripts listed in each category revealed that myocardin stimulated SMC genes an average of 47-fold, cardiac genes 9-fold, and skeletal muscle genes 0.9-fold (Table 1) .
Gene Ontology (GO) classification of the subset of annotated transcripts stimulated greater than 5-fold in response to myocardin identifies several genes involved in intermediary metabolism and cytoplasmic signaling cascades as downstream targets of myocardin, as might be expected for a mesodermal cell in the process of differentiating into muscle (Fig. 1B) .
SRF and SRF co-activators have been implicated in regulating both muscle genes and cellular growth and proliferation genes (Selvaraj and Prywes, 2004; . We analyzed the proportions of muscle genes activated by myocardin in comparison to the proportion of cell growth genes. Examining all genes increased (by Affymetrix MAS5.0 criteria) reveals a greater role for myocardin in regulating muscle genes than for regulation of cell growth genes: myocardin misexpression only stimulated 7% (55/797) of genes classified as regulating cellular proliferation, but 29% (98/334) of genes classified as regulating muscle development or function.
Myocardin null ES cells differentiate into SMCs with altered levels of SMC marker gene transcripts
The early lethality of myocardin null embryos precludes analysis of myocardin's role in the development of any tissue past E10.5. Therefore, we generated myocardin null and control ES cell lines of the same sex and genetic background from intercrosses of heterozygous myocardin mice and allowed them to differentiate in vitro as embryoid bodies in hanging drops, which gives consistent cardiac differentiation, and also in crowded Fflat_ cultures in the absence of LIF, which provides differentiation of all three muscle types. Control ES cells do not express myocardin during normal growth in high serum in the presence of LIF, but differentiate into myocardin-expressing cells which are presumably SMC or cardiac precursor cells (Fig. 2) . These cells express myocardin co-factors, including (Fig. 2) . Analyzing the expression of marker genes for cardiac and SM differentiation by RT-PCR showed no consistent deficit in cardiac or SM differentiation in myocardin null cells: a SM actin, a cardiac actin and SM-MHC were all expressed at comparable times during differentiation experiments between myocardin null and control cell lines, although SM-MHC expression was never high in either protocol (Fig. 2) . Comparison of the transcriptional profiles of 20 day flat differentiated myocardin À/À and myocardin +/+ ES cell cultures generated using Affymetrix mouse genome 2.0 microarrays revealed that no known CArG-dependent transcripts were significantly altered in the absence of myocardin (data not shown).
Spontaneously and rhythmically contracting foci were consistently observed in cells of either genotype under either differentiation protocol after 6 days of differentiation. The cells that contribute to these foci have previously been shown to be similar to cardiac cells, in that their contractions are communicated through gap junctions (Boheler et al., 2002) . Thus, myocardin does not appear to be required in developing mammalian cardiomyocytes for the elaboration of coordinated contractile activity. These foci were not observed to decrease contractile activity during further differentiation in cells of either genotype.
In order to obtain consistent SMC differentiation of ES cells in vitro, we employed a modified EB differentiation protocol in the presence of retinoids and cAMP (Sinha et al., 2004) . The myocardin null SMCs obtained using this protocol appeared to be phenotypically normal, expressing normal levels of SMC contractile proteins at similar levels as control ES cells as assayed by immunocytochemistry (Fig. 3) . The levels of the transcripts encoding these proteins, on the other hand, were consistently dysregulated in myocardin null ES cell cultures. At 15 days of differentiation, myocardin null ES cell cultures expressed increased levels of these transcripts (Fig. 4) . After 28 days of differentiation, there was a consistent 2-fold decrease in the levels of these transcripts. Thus, co-activation by myocardin is not required for the expression of these CArG-dependent SMC structural genes under all conditions, but in the absence of myocardin, levels of these transcripts are untimely and uncoordinated compared to differentiation of wild type cells.
Chimeric analysis of myocardin null ES cells
To further assess the potential role of myocardin in smooth muscle differentiation in vivo, we derived male h-galactosidase + myocardin À/+ and myocardin À/À ES cell lines from intercrosses between myocardin À/+ mice harboring the ROSA26 gene trap, which expresses h-galactosidase in all cell types (Zambrowicz et al., 1997) . Injecting myocardin À/+ or myocardin À/À ES cells into the inner cell mass of wild type host blastocysts yields conceptuses with wild type trophoblastderived tissues, while the embryonic vasculature is composed of a mixture of wild type and mutant cells. Thus, our chimeric analysis makes it possible to address whether myocardin is required cell-autonomously in the embryo only; previously, we described potentially lethal defects in both the embryonic and extraembryonic vasculature of myocardin À/À embryos .
Staining of chimeric embryos for h-galactosidase activity showed that control heterozygous ES cells were capable of contributing to all embryonic tissues examined (Fig. 5A and  data not shown) . Remarkably, examination of myocardin À/À , ROSA26/+ ES cell chimeras also showed no specific exclusion of myocardin À/À ES cells from SMC lineages at E12.5. In particular, Fig. 5B shows a developing aorta composed entirely of h-galactosidase-expressing myocardin null cells, with an intact endothelial cell layer and a surrounding thick group of cells, indicating that developing SMCs populated the endothelial tube normally. Likewise, myocardin À/À , ROSA26/+ cells could be observed in the SMC layer of the major vessels in older embryos (Fig. 5C ) and in adults (Figs. 5D -E) .
Immunohistochemical double-labeling h-galactosidase protein and a-SM actin showed that, as for the in vitrodifferentiated myocardin À/À ES cells, in vivo differentiated myocardin À/À , ROSA26/+ ES cells were capable of expressing a component of the SMC contractile apparatus (Fig. 6 ).
Discussion
In this study, we used loss-of-function and gain-offunction approaches in stem cells to analyze the role that myocardin plays in controlling the SMC transcriptosome and vascular differentiation. Transcriptional profiling of undifferentiated cells misexpressing myocardin showed that the transcriptional consequences of myocardin activity are largely confined to SMC and cardiac genes. Analyzing the endogenous levels of CArG-dependent SMC-specific transcripts in differentiating myocardin À/À ES cell lines showed Fig. 3 . Myocardin null and control ES cells differentiate in vitro into SMCs. Myocardin null and control ES cells were differentiated using a modified embryoid body differentiation protocol that enriches for smooth muscle cell differentiation. Differentiation cultures were fixed at 28 days and stained with antibodies against the SMC marker proteins smooth muscle myosin heavy chain (SM-MHC) and smooth muscle a actin (a-SMA) (red) and counterstained with DAPI (blue). , or as confluent ES cell cultures without LIF (flat differentiation) for the specified number of days, then total RNA was harvested and analyzed for the expression of the indicated transcripts by RT-PCR. ''d0'' refers to cells before differentiation, ''a-SKA'' refers to skeletal a actin, ''a-SMA'' refers to smooth muscle a actin and ''a-CA'' refers to cardiac a actin.
that myocardin is not absolutely required for the expression of SRF-dependent SMC genes, although transcripts encoding three critical SMC genes, a-SM actin, SM-MHC and SM22, were decreased in the absence of myocardin. Furthermore, we performed chimeric analysis in order to bypass the early lethality observed in myocardin À/À embryos, demonstrating that embryonic myocardin expression is not required cell-autonomously for grossly normal SMC differentiation in vivo.
Myocardin's unique role in aortic development
Extensive work shows that many muscle genes and almost all SMC genes are dependent on CArG boxes in their proximal promoter regions for expression (Miano, 2003) . Deleting SRF in smooth, skeletal and cardiac muscle cells leads to a lethal diminution in the levels of expression of CArG-dependent muscle structural genes Miano et al., 2004; Niu et al., 2005; Parlakian et al., 2004) . Transcriptional stimulation by SRF is co-activated by members of the myocardin family of transcription factors, composed of myocardin, MRTF-A and MRTF-B, each of which is capable of driving extremely high levels of expression of CArG-dependent muscle genes . This activity is an absolute requirement for proper expression of CArG-dependent muscle genes: dominant negative forms of myocardin and MRTF-A result in dramatic and lethal decreases in the expression of muscle structural and contractile genes Selvaraj and Prywes, 2003; Wang et al., 2001; Yoshida et al., 2003) .
A homozygous single-gene mutation in myocardin is lethal during the earliest stage of SMC development in vivo, and embryos lacking myocardin show no expression of the most terminal SMC differentiation marker, SM-MHC . However, we show that myocardin À/À ES cells can successfully populate the embryonic aorta during late embryogenesis and even adulthood. How can these findings be reconciled with our prior study showing that myocardin is essential for SMC differentiation during embryogenesis?
There are several possible explanations for why we recovered myocardin null SMCs. Myocardin may be required cellautonomously for SMC development in the dorsal aorta, but that requirement could be transient and satisfied at E10.5 or before by a small number of wild type cells which we cannot detect at later stages. It may also be that the requirement for myocardin in vascular SMC differentiation is non cell-autonomous-e.g., a small number of myocardin +/+ host cells could secrete a factor required for SMC differentiation. In support of this hypothesis, we note that aortas from high percentage myocardin À/À , ROSA26/+ adult mice always harbor a significant proportion of wild type cells (see Fig. 5D ). Alternatively, we favor the possibility that myocardin activity is not required in the dorsal aorta for embryonic viability, but instead is required in some extraembryonic vascular tissue(s).
Chimeric analyses, including tetraploid rescue, morula aggregation and the straightforward ES cell injections we present here, cannot conclusively determine which tissue requires myocardin activity for embryonic viability. Each of these manipulations can result in chimeric extraembryonic tissues (Beddington and Robertson, 1989) , leaving open the possibility that the requirement for myocardin for viability is non-cell autonomous. The current study only asks whether or not myocardin is required cell autonomously for SMC differentiation, not where myocardin is required for embryonic viability. Proof of which tissue requires myocardin activity for embryonic viability awaits the tissue-specific deletion of myocardin from subsets of extraembryonic or embryonic vascular tissues using a floxed allele of myocardin.
Assuming that myocardin is required cell-autonomously for vascular SMC differentiation in the dorsal aorta, why are MRTF-A or -B, which are broadly expressed and capable of driving high levels of SMC gene expression in vitro, unable to compensate for the lack of myocardin activity in myocardin Fig. 6 . Normal expression of a-smooth muscle actin protein by myocardin À/À SMC in vivo. Heterozygous and null myocardin ES cells genetically labeled hgalactosidase + with ROSA26 were injected into wild type blastocysts and sacrificed and cryosectioned at E16.5. Sections were labeled with anti-h-galactosidase in green (marking myocardin null cells) and anti-a SM actin in red. This section, just rostral to the aortic arch, depicts multiple myocardin null ES cell-derived SMC near the junction between two major vessels expressing a SM actin. knockout embryos? Recent work shows that MRTF-A can be sequestered in the cytoplasm and rendered transcriptionally inactive by actin (Miralles et al., 2003) . In differentiating striated muscle cells, a protein called STARS drives MRTF-A and -B into the nucleus, preventing the high levels of muscle actins required for muscle contraction from repressing MRTF-A and -B's transactivation of CArG-dependent muscle target genes (Kuwahara et al., 2005) . Any tissue which lacks STARS protein but requires the activity of a myocardin family member for proper expression of CArG-dependent genes would then be predicted to have defects in the expression of contractile proteins in myocardin mutants. It may be that expression of a SM actin or the actin rearrangements required for migration to the endothelial tube result in the sequestration of MRTF-A and -B in the cytoplasm of these cells, revealing a tissue-specific requirement for myocardin. Alternatively, MRTF-A and/or B may not compensate for the absence of myocardin in certain SMC tissues simply due to differences in transcriptional regulatory controls between these three genes, and their responsiveness to environmental cues present within developing SMC tissues.
Co-activators of SRF and muscle gene expression
SRF is required for the expression of CArG-dependent SMC genes under all conditions examined (Weinhold et al., 2000) , but the current results indicate that this is not true for myocardin. Myocardin null cells are capable of differentiating into SM-MHC + SMCs, a novel finding that we could not make previously due to the early lethality of myocardin null embryos. In vitro differentiated myocardin null ES cells express reduced levels of SMC transcripts, indicating that, although myocardin-independent mechanisms can provide a basal level of SM gene expression, myocardin is required for the high levels of expression normally present in a differentiated SMC.
In addition to being required for activation of muscle genes, SRF also activates genes which regulate cellular proliferation, including immediate early genes (Buchwalter et al., 2004) . Our results highlight a significant preference for activation of muscle genes by myocardin, consistent with previous work showing that myocardin promotes differentiation of muscle cells (Liu et al., 2005a,b; . There are several possible explanations for how myocardin achieves this selectivity. Previous work shows that the activation by myocardin or MRTFs of many SRF targets is antagonized by ternary complex factor (TCF) binding at sites adjacent to the SRE (Selvaraj and Prywes, 2004; . It is likely that such a mechanism is at work here, although efforts to connect every target gene's responsiveness to a particular set of cis-regulatory elements have been complicated by distal positioning of enhancer elements. Additionally, many other transcription factors have been shown to repress SRF activation at a subset of SRF target gene loci, including GATA factors (Oh et al., 2004; Yin and Herring, 2005) , Elk-1 (Wang et al., 2004 ), FHL2 (Philippar et al., 2004) and HOP (Chen et al., 2002a; Shin et al., 2002) . Myocardin most likely interacts with a transcriptional regulator that the MRTFs do not in order to selectively co-activate CArG-dependent muscle target genes.
The transcription of several genes encoding cardiac structural proteins and proteins required for coordinated electrical activity, such as those encoding a cardiac actin and the sodium/potassium exchanger, is also CArG-dependent (Belaguli et al., 2000; Cheng et al., 1999) . Although myocardin coordinates and regulates the expression of multiple CArG-dependent cardiac genes, it was previously found that misexpression of myocardin was not sufficient to induce beating or cardiac-like coordinated contraction in Xenopus animal cap assays (Small et al., 2005) . Consistent with this result, our experiments show that the loss of myocardin does not affect development of the beating phenotype in mammalian ES cells in vitro. Therefore, the CArG-dependency of these terminal differentiation markers of cardiac cells is either sufficiently fulfilled by SRF alone, or another SRF cofactor is capable of coactivating their expression to levels sufficient for the elaboration of junctioned, rhythmically contracting muscle tissue in vitro.
Taken together, our results indicate that myocardin is a potent effector of the SMC transcriptional program, and is required for normal expression of SMC transcripts during differentiation. In the absence of myocardin, SMC differentiation appears overtly normal and is sufficient for embryonic development (although possibly not extra-embryonic development) in vivo, but careful examination of SMC genes reveals deficiencies in the levels of these genes in vitro. It is likely that MRTF-A and -B can compensate for the lack of myocardin function in most contexts. A remaining question is whether coactivation of SRF by any myocardin family member is required for CArG-dependent SMC gene expression at all. That is, in the absence of myocardin, MRTF-A and MRTF-B, is the expression of CArG-dependent contractile genes absent? Answering this requires the analysis of double-and triple mutant combinations of myocardin, MRTF-A and -B, and possibly in vitro differentiation of cells derived from these mutants.
